Replies to post #85557 on Biotech Values

[go seek]

a knee-jerk market reaction on the NVS decision not to license...
will not be surprised to see IDIX move back above today's close of @2.50 in short order.

...So we get another company w/ strong anti-viral development experience to opt in. Any guesses on who Idenix may be talking to?

Gilead
Abbott
Glaxo Smith Kline
Schering Plough
Bristol Myers Squibb
Merck
Pfizer
Roche

Some of the above have significant efforts in the HCV space and 'may' fit very well with Idenix / nuc IDX184.

http://www.hcvdrugs.com/
#msg-42917735

[mcbio]

Re: NVS/IDX-184

I'm surprised at NVS' decision, not surprised that the stock dropped, but also see this as a buying opportunity. I plan to dollar-cost average more into IDIX either tomorrow or early next week depending on what happens to the share price. While one should rightly wonder why NVS didn't want to license the compound, this doesn't mean that IDIX will be unable to find an interested party. Based on the PoC data they have already shown for IDX-184, I find it hard to believe that they won't be able to land a nice deal for the compound.